Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children

Gantt, Soren; Kakuru, Abel; Wald, Anna; Walusansa, Victoria; Corey, Lawrence; Casper, Corey; Orem, Jackson

doi:10.1186/1750-9378-5-s1-a12

Cited by 10 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lymph nodes (LNs) are commonly involved. Gantt et al [12] from Uganda reported that 60% of the cases of KS in lymph nodes were in young children with relatively high CD4 counts. It is hypothesised that this occurs because a high level of circulating HHV8 immediately after an infection results in conversion to KS [13].…”

Section: Diagnosismentioning

confidence: 99%

“…KS is now largely an opportunistic malignancy of HIV disease. It is responsive to treatment but complete cure is probably only achieved in a child whose KS is focal or limited to very few sites [12]. Quality of life should be balanced against treatment with curative intent.…”

Section: Treatmentmentioning

confidence: 99%

“…Outcomes can be measured as cure and/or as improving the quality of life. Two retrospective audits, one from Uganda and one from South Africa report the treatment and outcome of 73 and 70 children respectively [12,23]. Eleven percent of children in Uganda and 20% in South Africa were already on ARTs before the start of chemotherapy.…”

Section: Treatment Regimensmentioning

confidence: 99%

See 2 more Smart Citations

The management of children with Kaposi sarcoma in resource limited settings

Molyneux

Davidson

Orem

et al. 2012

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Kaposi sarcoma (KS) is common where HIV infection is endemic. Antiretroviral therapy (ART) has reduced the incidence in well‐resourced settings but in some parts of the world access to ART is delayed. These recommendations are for use where only minimal requirements for treatment are available. Consensus was sought for the management of childhood HIV‐associated KS in this setting. There are no randomised controlled studies of chemotherapy for KS in children and these recommendations have drawn on consensus of a group of experts and published reports from studies in adults. Pediatr Blood Cancer 2013; 60: 538–542. © 2012 Wiley Periodicals, Inc.

show abstract

Section: Diagnosismentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

The management of children with Kaposi sarcoma in resource limited settings

Molyneux

Davidson

Orem

et al. 2012

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…[10][11][12] De los niños infectados con HIV en Uganda, 1,7% presentaron malignizaciones, de las cuales 90% fueron SK, con una mortalidad del 30%. 10 La presentación clínica como linfadenopatía es especialmente frecuente en los niños pequeños de esa zona.…”

Section: Discussionunclassified

“…10 La presentación clínica como linfadenopatía es especialmente frecuente en los niños pequeños de esa zona. 11 No hay evidencia adecuada en los niños que permita determinar si la terapia antirretroviral es suficiente o si es necesario agregar esquemas de quimioterapia para tratar estos tumores. 12 El aumento del riesgo de aparición de un tumor maligno después del trasplante de un órgano sólido en relación con la terapia inmunosupresora y las infecciones virales es bien conocido y se ha confirmado en publicaciones recientes.…”

Section: Discussionunclassified

Sarcoma de Kaposi por virus del herpes humano de tipo 8 en un receptor de trasplante hepático pediátrico. Caso clínico

Malla¹,

Perez²,

Cheang³

et al. 2013

Arch Argent Pediat

View full text Add to dashboard Cite

Arch Argent Pediatr 2013;111(5):e125-e128 / e125Presentación de casos clínicos RESUMEN Los pacientes que reciben tratamiento inmunosupresor están en riesgo de desarrollar tumores malignos. La infección primaria o reactivación del virus del herpes humano de tipo 8 (HHV-8) puede predisponer al sarcoma de Kaposi después del trasplante de un órgano sólido. En los receptores de trasplantes pediátricos, este sarcoma tiene baja incidencia y mal pronóstico. Se informa la presentación clínica de un sarcoma de Kaposi en un ganglio linfático luego de una infección por HHV-8 en un niño a los 4 meses del trasplante hepático. El paciente tuvo buena evolución con suspensión del tacrolimus y conversión a sirolimus un mes después del diagnóstico. En nuestro conocimiento, este es el primer caso de sarcoma de Kaposi en un receptor pediátrico de trasplante hepático informado en nuestro país y creemos que esta entidad debería considerarse como diagnóstico diferencial en las complicaciones postrasplante. Palabras clave: trasplante hepático, pediatría, virus del herpes humano de tipo 8, malignidad, sarcoma de Kaposi.

show abstract

Childhood cancer in Africa

Kruger

Hendricks

Davidson

et al. 2013

Pediatric Blood & Cancer

View full text Add to dashboard Cite

The majority of children with cancer live in low- and middle-income countries (LMICs) with little or no access to cancer treatment. The purpose of the paper is to describe the current status of childhood cancer treatment in Africa, as documented in publications, dedicated websites and information collected through surveys. Successful twinning programmes, like those in Malawi and Cameroon, as well as the collaborative clinical trial approach of the Franco-African Childhood Cancer Group (GFAOP), provide good models for childhood cancer treatment. The overview will hopefully influence health-care policies to facilitate access to cancer care for all children in Africa.

show abstract

Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children

Cited by 10 publications

References 23 publications

The management of children with Kaposi sarcoma in resource limited settings

The management of children with Kaposi sarcoma in resource limited settings

Sarcoma de Kaposi por virus del herpes humano de tipo 8 en un receptor de trasplante hepático pediátrico. Caso clínico

Childhood cancer in Africa

Contact Info

Product

Resources

About